An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs SAR 422459 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors Oxford BioMedica; Sanofi
- 18 Jan 2018 Planned number of patients changed from 28 to 46.
- 21 Dec 2017 Planned End Date changed from 13 Nov 2034 to 27 Nov 2034.
- 21 Dec 2017 Planned primary completion date changed from 13 Nov 2034 to 27 Nov 2034.